{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:38:47Z","timestamp":1792669127746,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-026-01724-7","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:06:47Z","timestamp":1781186807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Romosozumab for cancer treatment-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer: a case series"],"prefix":"10.1007","volume":"21","author":[{"given":"Shohei","family":"Tsujino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Tozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabu","family":"Gokita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"10001","key":"1724_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1","journal-title":"Lancet"},{"key":"1724_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS (2005) Fracture risk among breast cancer survivors: results from the Women\u2019s health initiative observational study. Arch Intern Med 165:552\u2013558. https:\/\/doi.org\/10.1001\/archinte.165.5.552","journal-title":"Arch Intern Med"},{"key":"1724_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11764-017-0666-4","volume":"12","author":"JM Neuner","year":"2018","unstructured":"Neuner JM, Shi Y, Kong AL, Kamaraju S, Smith EC, Smallwood AJ, Laud PW, Charlson JA (2018) Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. J Cancer Surviv 12:268\u2013275. https:\/\/doi.org\/10.1007\/s11764-017-0666-4","journal-title":"J Cancer Surviv"},{"key":"1724_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1759720X18759291","volume":"10","author":"OL Tseng","year":"2018","unstructured":"Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG (2018) Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 10:71\u201390. https:\/\/doi.org\/10.1177\/1759720X18759291","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1724_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-015-3661-3","volume":"155","author":"N Schmidt","year":"2016","unstructured":"Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P (2016) The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat 155:151\u2013157","journal-title":"Breast Cancer Res Treat"},{"key":"1724_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00774-020-01087-0","volume":"38","author":"S Fukumoto","year":"2020","unstructured":"Fukumoto S, Soen S, Taguchi T, Ishikawa T, Matsushima H, Terauchi M, Horie S, Yoneda T, Sugimoto T, Matsumoto T, Subcommittee for CTIBL in the JSBMR (2020) Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab 38:141\u2013144. https:\/\/doi.org\/10.1007\/s00774-020-01087-0","journal-title":"J Bone Miner Metab"},{"key":"1724_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fendo.2018.00505","volume":"9","author":"SK Ramchand","year":"2018","unstructured":"Ramchand SK, Seeman E (2018) Advances and unmet needs in the therapeutics of bone fragility. Front Endocrinol 9:505. https:\/\/doi.org\/10.3389\/fendo.2018.00505","journal-title":"Front Endocrinol"},{"key":"1724_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Matsumoto T (2021) Sclerostin: from bench to bedside. J Bone Miner Metab 39:332\u2013340. https:\/\/doi.org\/10.1007\/s00774-020-01176-0","journal-title":"J Bone Miner Metab"},{"key":"1724_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"1724_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"1724_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125543","volume":"5","author":"E Hesse","year":"2019","unstructured":"Hesse E, Schr\u00f6der S, Brandt D, Pamperin J, Saito H, Taipaleenm\u00e4ki H (2019) Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight 5:e125543. https:\/\/doi.org\/10.1172\/jci.insight.125543","journal-title":"JCI Insight"},{"key":"1724_CR12","doi-asserted-by":"publisher","first-page":"11399","DOI":"10.1038\/s41598-017-11913-7","volume":"7","author":"M Zhu","year":"2017","unstructured":"Zhu M, Liu C, Li S, Zhang S, Yao Q, Song Q (2017) Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci Rep 7:11399. https:\/\/doi.org\/10.1038\/s41598-017-11913-7","journal-title":"Sci Rep"},{"issue":"3","key":"1724_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1007\/s12020-025-04434-1","volume":"90","author":"R Colle","year":"2025","unstructured":"Colle R, Piasentier A, Fanti A et al (2025) Safety of Romosozumab in women with cancer and osteoporosis at high risk of fractures. Endocrine 90(3):1472\u20131478. https:\/\/doi.org\/10.1007\/s12020-025-04434-1","journal-title":"Endocrine"},{"key":"1724_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198\u2013202. https:\/\/doi.org\/10.1002\/jbmr.3051","journal-title":"J Bone Miner Res"},{"key":"1724_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00198-024-07155-9","volume":"35","author":"J Everts-Graber","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S et al (2024) The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int 35:1605\u20131613. https:\/\/doi.org\/10.1007\/s00198-024-07155-9","journal-title":"Osteoporos Int"},{"key":"1724_CR16","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1111\/cas.15765","volume":"114","author":"T Hiraga","year":"2023","unstructured":"Hiraga T, Horibe K, Koide M, Yamashita T, Kobayashi Y (2023) Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells. Cancer Sci 114:2460\u20132470. https:\/\/doi.org\/10.1111\/cas.15765","journal-title":"Cancer Sci"}],"updated-by":[{"DOI":"10.1007\/s11657-026-01779-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000}}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01724-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01724-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01724-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:46:00Z","timestamp":1792665960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01724-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01724-7","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The Abstract of this article was inadvertently published with an incorrect statement. The mean duration of aromatase inhibitor therapy prior to treatment was stated as \u201c35.3 months to 36.9 months\u201d; the correct text should read \u201c36.9 months.\u201d","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected accordingly.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11657-026-01779-6","URL":"https:\/\/doi.org\/10.1007\/s11657-026-01779-6","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Saitama Cancer Center (Approval No. 2282) and was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"89"}}